Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients

Bone Marrow Transplantation

Volumn 42, Issue 5, 2008, Pages 345-349

  Herbers, A H E ^a   Blijlevens, N M A ^a   Donnelly, J P ^a   de Witte, T J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CIPROFLOXACIN; CITRULLINE; MELPHALAN; VALACICLOVIR;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; BLOOD CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG FEVER; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HUMAN; INTESTINE INJURY; INTESTINE MUCOSA; LEUKOPENIA; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NEUTROPENIA; OUTCOME ASSESSMENT; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STOMATITIS; STREPTOCOCCUS MITIS;

ADULT; AGED; BACTEREMIA; CITRULLINE; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 52149107562     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.170     Document Type: Article

References (30)

1. Blijlevens NMA, Lutgens LCHW, Schattenberg AVMB, De Pauw BE. Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant 2004; 34: 193-196.
2. Ellis M. Preventing microbial translocation in haematological malignancy. Br J Haematol 2004; 125: 282-293.
3. Crenn P, Vahedi K, Lavergne-Slove A, Cynober L, Matuchansky C, Messing B. Plasma citrulline: A marker of enterocyte mass in villous atrophy-associated small bowel disease. Gastroenterology 2003; 124: 1210-1219.
4. Blijlevens NMA, Donnelly JP, De Pauw BE. Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2005; 36: 703-707.
5. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82: 2275-2281.
6. Jones BN, Giligan JP. o-Phthaldialdehyde precolumn derivatization and reversed-phase high-performance liquid chromatography of polypeptide hydrolysates and physiological fluids. J Chromatogr 1983; 266 471-482.
7. Donnelly JP, Muus P, Schattenberg A, De Witte T, Horrevorts A, De Pauw BE. A scheme for daily monitoring of oral mucositis in allogenic BMT recipients. Bone Marrow Transplant 1992; 9: 409-413.
8. Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haematopoietic progenitor rescue. Br J Haematol 2000; 110: 292-299.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
10. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leucocytes and infections in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
11. Bow EJ. Management of the febrile neutropenic cancer patient: Lessons from 40 years of study. Clin Microbiol Infect 2005; 11: 24-29.
12. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem cell transplantation. J Clin Oncol 2001; 19 2201-2205.
13. Blijlevens N, Schwenkglenks M, Bacon P, DAddio A, Einsele H, Maertens J et al. Prospective oral mucositis audit: Oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy. European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519-1525.
14. Blijlevens NMA, van't Land B, Donnelly JP, M'Rabet L, De Pauw BE. Measuring mucosal damage induced by cytotoxic therapy. Support Care Cancer 2004; 12: 227-233.
15. Von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehman L, Breij P, Hahn C et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: Procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004; 23: 539-544.
16. Ortega M, Ravira M, Almela M, Dela Bellacasa JP, Carreras E, Menza J. Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. Bone Marrow Transplant 2004; 33: 741-744.
17. Tsuji E, Hiki N, Nomura S, Fukushima R, Kojima J, Ogawa T et al. Simultaneous onset of acute inflammatory response, sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy. Int J Cancer 2003; 1: 303-308.
18. Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clin Infect Dis 1996; 23: 795-805.
19. Bouza E, Sousa D, Rodriquez-Creixems M, Garcia Lechuz J, Munoz P. Is the volume of blood cultured still a significant factor in the diagnosis of bloodstream infections. J Clin Microbiol 2007; 45: 2765-2769.
20. Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci USA 2006; 103: 732-737.
21. Gamis AS, Howells WB, Swarte-Wallace J, Feusner JH, Buckley JD, Woods WG. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: A report from the Children's cancer group study CCG-2891. J Clin Oncol 2000; 18: 1845-1855.
22. Costa SF, Micelli MH, Annaissie EJ. Mucosa or skin as source of coagulase-negative staphylococcal bacteraemia? Lancet Inf Dis 2004; 4: 278-286.
23. Costa SF, Barone AA, Miceli MH, Van der Heijden IM, Soares RE, Levin AS et al. Colonization and molecular epidemiology of coagulase-negative Staphylococcal bacteremia in cancer patients: A pilot study. Am J Infect Control 2006; 34: 36-40.
24. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burden of cancer therapy: Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98: 1531-1539.
25. Ellis M, Zwaan F, Hedstrom U, Poynton C, Kristensen J, Jumaa P et al. Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: A double-blind placebo-controlled randomised trial. Lancet 2003; 25: 275-280.
26. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancer. N Engl J Med 2004; 351: 2590-2598.
27. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R et al. The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051.
28. Oude Nijhuis CSM, Vellenga E, Daenen SMGJ, Kamps WA, de Bont ESMJ. Endothelial cells are main producers of interleukin 8 through toll-like receptor 3 and 4 signalling during bacterial infection in leukopenic cancer patients. Clin Diagn Lab Immunol 2003; 10: 558-563.
29. Engel A, Mack E, Kern P, Kern WV. An analysis of interleukin-8, interleukin-6 and C-reactive protein concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection 1998; 26: 213-221.
30. De Bont ES, Vellenga E, Swaanenburg JC, Fidler V, Visser-van Brummen PJ, Kamps WA. Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol 1999; 107: 375-380.